Phase II Clinical Trials of Novel Therapies for Lung Diseases (U01)
The summary for the Phase II Clinical Trials of Novel Therapies for Lung Diseases (U01) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Phase II Clinical Trials of Novel Therapies for Lung Diseases (U01): Purpose. This Funding Opportunity Announcement (FOA) issued by the National Heart, Lung, and Blood Institute, National Institutes of Health, solicits grant applications from institutions/organizations to conduct proof-of- concept Phase II clinical trials that test a novel intervention for a lung disease or a cardiopulmonary disorder from sleep that have the potential to significantly change clinical management. In addition, each application must include at least one ancillary study tightly related to the clinical question. Mechanism of Support. This FOA will utilize the NIH cooperative agreement (U01) grant mechanism. Funds Available and Anticipated Number of Awards. The NHLBI intends to commit up to $40,600,000 (total costs) over 4 years. It is anticipated that up to two awards will be made for each of 3 receipt dates for a total of four to six awards.
|Federal Grant Title:||Phase II Clinical Trials of Novel Therapies for Lung Diseases (U01)|
|Federal Agency Name:||National Institutes of Health|
|Type of Opportunity:||Discretionary|
|Funding Opportunity Number:||RFA-HL-10-003|
|Type of Funding:||Cooperative Agreement|
|CFDA Descriptions:||National Center on Sleep Disorders Research|
|Current Application Deadline:||Sep 15, 2010|
|Original Application Deadline:||Sep 15, 2010|
|Posted Date:||Feb 23, 2009|
|Creation Date:||Feb 23, 2009|
|Archive Date:||Oct 16, 2010|
|Total Program Funding:||$40,600,000|
|Maximum Federal Grant Award:||$800,000|
|Minimum Federal Grant Award:|
|Expected Number of Awards:||6|
|Cost Sharing or Matching:||No|
- Applicants Eligible for this Grant
- State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification)
- Additional Information on Eligibility
- Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
- Link to Full Grant Announcement
- Information not provided
- Grant Announcement Contact
- NIH OER WebmasterFBOWebmaster@OD.NIH.GOV
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [FBOWebmaster@OD.NIH.GOV]
- Similar Government Grants
- • Multidisciplinary Approaches to HIV-Associated Comorbidities and Prioritizing Intervention...
- • Using Syndemics to Understand HLBS Disease Emergence and Progression in People with HIV (P...
- • Emergency Awards: RADx-rad Predicting Viral-Associated Inflammatory Disease Severity in Ch...
- • Hybrid Effectiveness-Implementation Trials for Heart, Lung, Blood, and Sleep Diseases in t...
- • Implementation Research to Improve Case Finding, Cascade Screening, and Treatment for Fami...
- • Ancillary Studies in Clinical Trials (R01)
- • Opportunity PA-08-021
- • Research Demonstration and Dissemination Grants (R18)
- More Grants from the National Institutes of Health
- • Integrative Neuroscience Initiative on Alcoholism (INIA) Consortia Administrative Resource...
- • Integrative Neuroscience Initiative on Alcoholism (INIA) Consortia Research Resource (U24)...
- • New Cohorts for Environmental Exposures and Cancer Risk (CEECR; UG3/UH3 Clinical Trial Not...
- • Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical ...
- • Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Tria...